Impaired T-cell function in B-cell lymphoma: A direct consequence of events at the immunological synapse?

Frontiers in Immunology

Volumn 6, Issue JUN, 2015, Pages

  Nassef Kadry Naguib Roufaiel, Marian ^a   Wells, James W ^a   Steptoe, Raymond J ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

Immunological synapse; Lymphoma; T cell function; T cell tolerance

Indexed keywords

INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 17; T LYMPHOCYTE RECEPTOR;

ADOPTIVE IMMUNOTHERAPY; ANTIGEN PRESENTATION; ANTIGEN PRESENTING CELL; AUTOIMMUNITY; B CELL LYMPHOMA; CELL DIFFERENTIATION; CELL FUNCTION; CELL INTERACTION; CELL PROLIFERATION; CELLULAR IMMUNITY; GENE EXPRESSION; GENE MUTATION; IMMUNE DEFICIENCY; IMMUNOLOGICAL SYNAPSE; IMMUNOMODULATION; MEMORY CELL; NONHUMAN; REGULATORY T LYMPHOCYTE; SHORT SURVEY; TUMOR ASSOCIATED LEUKOCYTE;

EID: 84935086452     PISSN: None     EISSN: 16643224     Source Type: Journal    
DOI: 10.3389/fimmu.2015.00258     Document Type: Short Survey

References (142)

1. Kuppers R. Mechanisms of B-cell lymphoma pathogenesis. Nat Rev Cancer (2005) 5:251-62. doi: 10.1038/nrc1589
2. National Cancer Institute Non-Hodgkin Lymphoma. Available from: http://www.cancer.gov/cancertopics/types/non-hodgkin (accessed October 27 2014)
3. National Cancer Institute. A Snapshot of Lymphoma. Available from: http://www.cancer.gov/researchandfunding/snapshots/lymphoma (accessed December 22 2014).
4. Penn I. Depressed immunity and the development of cancer. Cancer Detect Prev (1994) 18:241-52.
5. Goedert JJ, Cote TR, Virgo P, Scoppa SM, Kingma DW, Gail MH, et al. Spectrum of AIDS-associated malignant disorders. Lancet (1998) 351:1833-9. doi:10.1016/S0140-6736(97)09028-4
6. Hadden JW. Immunodeficiency and cancer: prospects for correction. Int Immunopharmacol (2003) 3:1061-71. doi:10.1016/s1567-5769(03)00060-2
7. Bollard CM, Rooney CM, Heslop HE. T-cell therapy in the treatment of post-transplant lymphoproliferative disease. Nat Rev Clin Oncol (2012) 9:510-9. doi:10.1038/nrclinonc.2012.111
8. Guy K, Krajewski AS, Dewar AE. Expression of MHC class II antigens in human B-cell leukaemia and non-Hodgkin's lymphoma. Br J Cancer (1986) 53:161-73. doi:10.1038/bjc.1986.31
9. Moller P, Lammler B, Herrmann B, Otto HF, Moldenhauer G, Momburg F. The primary mediastinal clear cell lymphoma of B-cell type has variable defects in MHC antigen expression. Immunology (1986) 59:411-7.
10. Booman M, Szuhai K, Rosenwald A, Hartmann E, Kluin-Nelemans H, de Jong D, et al. Genomic alterations and gene expression in primary diffuse large B-cell lymphomas of immune-privileged sites: the importance of apoptosis and immunomodulatory pathways. J Pathol (2008) 216:209-17. doi:10.1002/path.2399
11. Rimsza LM, Roberts RA, Miller TP, Unger JM, LeBlanc M, Braziel RM, et al. Loss of MHC class II gene and protein expression in diffuse large B-cell lymphoma is related to decreased tumor immunosurveillance and poor patient survival regardless of other prognostic factors: a follow-up study from the Leukemia and Lymphoma Molecular Profiling Project. Blood (2004) 103:4251-8. doi:10.1182/blood-2003-07-2365
12. Calcinotto A, Filipazzi P, Grioni M, Iero M, De Milito A, Ricupito A, et al. Modulation of microenvironment acidity reverses anergy in human and murine tumor-infiltrating T lymphocytes. Cancer Res (2012) 72:2746-56. doi:10.1158/0008-5472.can-11-1272
13. Gatenby RA, Gillies RJ. Why do cancers have high aerobic glycolysis? Nat Rev Cancer (2004) 4:891-9. doi:10.1038/nrc1478
14. Rodriguez PC, Hernandez CP, Quiceno D, Dubinett SM, Zabaleta J, Ochoa JB, et al. Arginase I in myeloid suppressor cells is induced by COX-2 in lung carcinoma. J Exp Med (2005) 202:931-9. doi:10.1084/jem.20050715
15. Uyttenhove C, Pilotte L, Theate I, Stroobant V, Colau D, Parmentier N, et al. Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase. Nat Med (2003) 9:1269-74. doi:10.1038/nm934
16. Zou W. Regulatory T cells, tumour immunity and immunotherapy. Nat Rev Immunol (2006) 6:295-307. doi:10.1038/nri1806
17. Gabrilovich DI, Nagaraj S. Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol (2009) 9:162-74. doi:10.1038/nri2506
18. Moormann AM, Heller KN, Chelimo K, Embury P, Ploutz-Snyder R, Otieno JA, et al. Children with endemic Burkitt lymphoma are deficient in EBNA1-specific IFN-gamma T cell responses. Int J Cancer (2009) 124:1721-6. doi:10.1002/ijc.24014
19. Gandhi MK, Lambley E, Duraiswamy J, Dua U, Smith C, Elliott S, et al. Expression of LAG-3 by tumor-infiltrating lymphocytes is coincident with the suppression of latent membrane antigen-specific CD8+ T-cell function in Hodgkin lymphoma patients. Blood (2006) 108:2280-9. doi:10.1182/blood-2006-04-015164
20. Li J, Zeng XH, Mo HY, Rolén U, Gao YF, Zhang XS, et al. Functional inactivation of EBV-specific T-lymphocytes in nasopharyngeal carcinoma: implications for tumor immunotherapy. PLoS One (2007) 2:e1122. doi:10.1371/journal.pone.0001122
21. Fogg MH, Wirth LJ, Posner M, Wang F. Decreased EBNA-1-specific CD8+ T cells in patients with Epstein-Barr virus-associated nasopharyngeal carcinoma. Proc Natl Acad Sci U S A (2009) 106:3318-23. doi:10.1073/pnas.0813320106
22. Frisan T, Sjoberg J, Dolcetti R, Boiocchi M, De Re V, Carbone A, et al. Local suppression of Epstein-Barr virus (EBV)-specific cytotoxicity in biopsies of EBVpositive Hodgkin's disease. Blood (1995) 86:1493-501.
23. Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer (2012) 12:252-64. doi:10.1038/nrc3239
24. Crespo J, Sun H, Welling TH, Tian Z, Zou W. T cell anergy, exhaustion, senescence, and stemness in the tumor microenvironment. Curr Opin Immunol (2013) 25:214-21. doi:10.1016/j.coi.2012.12.003
25. Zippelius A, Batard P, Rubio-Godoy V, Bioley G, Lienard D, Lejeune F, et al. Effector function of human tumor-specific CD8 T cells in melanoma lesions: a state of local functional tolerance. Cancer Res (2004) 64:2865-73. doi:10.1158/0008-5472.CAN-03-3066
26. Rosenberg SA, Sherry RM, Morton KE, Scharfman WJ, Yang JC, Topalian SL, et al. Tumor progression can occur despite the induction of very high levels of self/tumor antigen-specific CD8+ T cells in patients with melanoma. J Immunol (2005) 175:6169-76. doi:10.4049/jimmunol.175.9.6169
27. Ahmadzadeh M, Johnson LA, Heemskerk B, Wunderlich JR, Dudley ME, White DE, et al. Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired. Blood (2009) 114:1537-44. doi:10.1182/blood-2008-12-195792
28. Fourcade J, Sun Z, Pagliano O, Guillaume P, Luescher IF, Sander C, et al. CD8(+) T cells specific for tumor antigens can be rendered dysfunctional by the tumor microenvironment through upregulation of the inhibitory receptors BTLA and PD-1. Cancer Res (2012) 72:887-96. doi:10.1158/0008-5472.can-11-2637
29. Baitsch L, Baumgaertner P, Devevre E, Raghav SK, Legat A, Barba L, et al. Exhaustion of tumor-specific CD8(+) T cells in metastases from melanoma patients. J Clin Invest (2011) 121:2350-60. doi:10.1172/jci46102
30. Steptoe RJ, Ritchie JM, Wilson NS, Villadangos JA, Lew AM, Harrison LC. Cognate CD4+ help elicited by resting dendritic cells does not impair the induction of peripheral tolerance in CD8+ T cells. J Immunol (2007) 178:2094-103. doi:10.4049/jimmunol.178.4.2094
31. Bonifaz L, Bonnyay D, Mahnke K, Rivera M, Nussenzweig MC, Steinman RM. Efficient targeting of protein antigen to the dendritic cell receptor DEC-205 in the steady state leads to antigen presentation on major histocompatibility complex class I products and peripheral CD8+ T cell tolerance. J Exp Med (2002) 196:1627-38. doi:10.1084/jem.20021598
32. Buhlmann JE, Foy TM, Aruffo A, Crassi KM, Ledbetter JA, Green WR, et al. In the absence of a CD40 signal, B cells are tolerogenic. Immunity (1995) 2:645-53. doi:10.1016/1074-7613(95)90009-8
33. Townsend SE, Goodnow CC. Abortive proliferation of rare T cells induced by direct or indirect antigen presentation by rare B cells in vivo. J Exp Med (1998) 187:1611-21. doi:10.1084/jem.187.10.1611
34. Eynon EE, Parker DC. Parameters of tolerance induction by antigen targeted to B lymphocytes. J Immunol (1993) 151:2958-64.
35. Bennett SR, Carbone FR, Toy T, Miller JF, Heath WR. B cells directly tolerize CD8(+) T cells. J Exp Med (1998) 188:1977-83. doi:10.1084/jem.188.11.1977
36. Werner-Klein M, Dresch C, Marcon IP, Brocker T. Transcriptional targeting of B cells for induction of peripheral CD8 T cell tolerance. J Immunol (2007) 178:7738-46. doi:10.4049/jimmunol.178.12.7738
37. Dalai SK, Mirshahidi S, Morrot A, Zavala F, Sadegh-Nasseri S. Anergy in memory CD4+ T cells is induced by B cells. J Immunol (2008) 181:3221-31. doi:10.4049/jimmunol.181.5.3221
38. Kenna TJ, Waldie T, McNally A, Thomson M, Yagita H, Thomas R, et al. Targeting antigen to diverse APCs inactivates memory CD8+ T cells without eliciting tissue-destructive effector function. J Immunol (2010) 184:598-606. doi:10.4049/jimmunol.0900032
39. Morlacchi S, Soldani C, Viola A, Sarukhan A. Self-antigen presentation by mouse B cells results in regulatory T-cell induction rather than anergy or clonal deletion. Blood (2011) 118:984-91. doi:10.1182/blood-2011-02-336115
40. Lee KM, Stott RT, Zhao G, SooHoo J, Xiong W, Lian MM, et al. TGF-beta-producing regulatory B cells induce regulatory T cells and promote transplantation tolerance. Eur J Immunol (2014) 44:1728-36. doi:10.1002/eji.201344062
41. Nouel A, Pochard P, Simon Q, Segalen I, Le Meur Y, Pers JO, et al. B-Cells induce regulatory T cells through TGF-beta/IDO production in A CTLA-4 dependent manner. J Autoimmun (2015) 59:53-60. doi:10.1016/j.jaut.2015.02.004
42. Candando KM, Lykken JM, Tedder TF. B10 cell regulation of health and disease. Immunol Rev (2014) 259:259-72. doi:10.1111/imr.12176
43. Donnou S, Galand C, Touitou V, Saut'es-Fridman C, Fabry Z, Fisson S. Murine models of B-Cell lymphomas: promising tools for designing cancer therapies. Adv Hematol (2012) 2012:701704. doi:10.1155/2012/701704
44. Staveley-O'Carroll K, Sotomayor E, Montgomery J, Borrello I, Hwang L, Fein S, et al. Induction of antigen-specific T cell anergy: an early event in the course of tumor progression. Proc Natl Acad Sci U S A (1998) 95:1178-83. doi:10.1073/pnas.95.3.1178
45. Horna P, Cuenca A, Cheng F, Brayer J, Wang HW, Borrello I, et al. In vivo disruption of tolerogenic cross-presentation mechanisms uncovers an effective T-cell activation by B-cell lymphomas leading to antitumor immunity. Blood (2006) 107:2871-8. doi:10.1182/blood-2005-07-3014
46. Sotomayor EM, Borrello I, Rattis FM, Cuenca AG, Abrams J, Staveley-O'Carroll K, et al. Cross-presentation of tumor antigens by bone marrow-derived antigen-presenting cells is the dominant mechanism in the induction of T-cell tolerance during B-cell lymphoma progression. Blood (2001) 98:1070-7. doi:10.1182/blood.V98.4.1070
47. Prato S, Mintern JD, Lahoud MH, Huang DC, Villadangos JA. Induction of antigen-specific effector-phase tolerance following vaccination against a previously ignored B-cell lymphoma. Immunol Cell Biol (2011) 89:595-603. doi:10.1038/icb.2010.131
48. Gerbitz A, Sukumar M, Helm F, Wilke A, Friese C, Fahrenwald C, et al. Stromal interferon-? signaling and cross-presentation are required to eliminate antigen-loss variants of B cell lymphomas in mice. PLoS One (2012) 7:e34552. doi:10.1371/journal.pone.0034552
49. Prato S, Zhan Y, Mintern JD, Villadangos JA. Rapid deletion and inactivation of CTLs upon recognition of a number of target cells over a critical threshold. J Immunol (2013) 191:3534-44. doi:10.4049/jimmunol.1300803
50. Dustin ML. A dynamic view of the immunological synapse. Semin Immunol (2005) 17:400-10. doi:10.1016/j.smim.2005.09.002
51. Yokosuka T, Saito T. The immunological synapse, TCR microclusters, and T cell activation. Curr Top Microbiol Immunol (2010) 340:81-107. doi:10.1007/978-3-642-03858-7_5
52. Dustin ML, Chakraborty AK, Shaw AS. Understanding the structure and function of the immunological synapse. Cold Spring Harb Perspect Biol (2010) 2:a002311. doi:10.1101/cshperspect.a002311
53. Thauland TJ, Parker DC. Diversity in immunological synapse structure. Immunology (2010) 131:466-72. doi:10.1111/j.1365-2567.2010.03366.x
54. Varma R, Campi G, Yokosuka T, Saito T, Dustin ML. T cell receptor-proximal signals are sustained in peripheral microclusters and terminated in the central supramolecular activation cluster. Immunity (2006) 25:117-27. doi:10.1016/j.immuni.2006.04.010
55. Monks CR, Freiberg BA, Kupfer H, Sciaky N, Kupfer A. Three-dimensional segregation of supramolecular activation clusters in T cells. Nature (1998) 395:82-6. doi:10.1038/25764
56. Hayashi K, Altman A. Filamin A is required for T cell activation mediated by protein kinase C-theta. J Immunol (2006) 177:1721-8. doi:10.4049/jimmunol.177.3.1721
57. Yokosuka T, Kobayashi W, Sakata-Sogawa K, Takamatsu M, Hashimoto-Tane A, Dustin ML, et al. Spatiotemporal regulation of T cell costimulation by TCR-CD28 microclusters and protein kinase C theta translocation. Immunity (2008) 29:589-601. doi:10.1016/j.immuni.2008.08.011
58. Brossard C, Feuillet V, Schmitt A, Randriamampita C, Romao M, Raposo G, et al. Multifocal structure of the T cell-dendritic cell synapse. Eur J Immunol (2005) 35:1741-53. doi:10.1002/eji.200425857
59. Fisher PJ, Bulur PA, Vuk-Pavlovic S, Prendergast FG, Dietz AB. Dendritic cell microvilli: a novel membrane structure associated with the multifocal synapse and T-cell clustering. Blood (2008) 112:5037-45. doi:10.1182/blood-2008-04-149526
60. Tseng SY, Waite JC, Liu M, Vardhana S, Dustin ML. T cell-dendritic cell immunological synapses contain TCR-dependent CD28-CD80 clusters that recruit protein kinase C theta. J Immunol (2008) 181:4852-63. doi:10.4049/jimmunol.181.7.4852
61. Grakoui A, Bromley SK, Sumen C, Davis MM, Shaw AS, Allen PM, et al. The immunological synapse: a molecular machine controlling T cell activation. Science (1999) 285:221-7. doi:10.1126/science.285.5425.221
62. Sims TN, Dustin ML. The immunological synapse: integrins take the stage. Immunol Rev (2002) 186:100-17. doi:10.1034/j.1600-065X.2002.18610.x
63. Dustin ML, Springer TA. T-cell receptor cross-linking transiently stimulates adhesiveness through LFA-1. Nature (1989) 341:619-24. doi:10.1038/341619a0
64. Springer TA, Dustin ML. Integrin inside-out signaling and the immunological synapse. Curr Opin Cell Biol (2012) 24:107-15. doi:10.1016/j.ceb.2011.10.004
65. Katagiri K, Maeda A, Shimonaka M, Kinashi T. RAPL, a Rap1-binding molecule that mediates Rap1-induced adhesion through spatial regulation of LFA-1. Nat Immunol (2003) 4:741-8. doi:10.1038/ni950
66. Smith A, Stanley P, Jones K, Svensson L, McDowall A, Hogg N. The role of the integrin LFA-1 in T-lymphocyte migration. Immunol Rev (2007) 218:135-46. doi:10.1111/j.1600-065X.2007.00537.x
67. Graf B, Bushnell T, Miller J. LFA-1-mediated T cell costimulation through increased localization of TCR/class II complexes to the central supramolecular activation cluster and exclusion of CD45 from the immunological synapse. J Immunol (2007) 179:1616-24. doi:10.4049/jimmunol.179.3.1616
68. Leupin O, Zaru R, Laroche T, Muller S, Valitutti S. Exclusion of CD45 from the T-cell receptor signaling area in antigen-stimulated T lymphocytes. Curr Biol (2000) 10:277-80. doi:10.1016/S0960-9822(00)00362-6
69. Hartman NC, Nye JA, Groves JT. Cluster size regulates protein sorting in the immunological synapse. Proc Natl Acad Sci U S A (2009) 106:12729-34. doi:10.1073/pnas.0902621106
70. Yokosuka T, Sakata-Sogawa K, Kobayashi W, Hiroshima M, Hashimoto-Tane A, Tokunaga M, et al. Newly generated T cell receptor microclusters initiate and sustain T cell activation by recruitment of Zap70 and SLP-76. Nat Immunol (2005) 6:1253-62. doi:10.1038/ni1272
71. Vardhana S, Choudhuri K, Varma R, Dustin ML. Essential role of ubiquitin and TSG101 protein in formation and function of the central supramolecular activation cluster. Immunity (2010) 32:531-40. doi:10.1016/j.immuni.2010.04.005
72. Valitutti S, Muller S, Salio M, Lanzavecchia A. Degradation of T cell receptor (TCR)-CD3-zeta complexes after antigenic stimulation. J Exp Med (1997) 185:1859-64. doi:10.1084/jem.185.10.1859
73. Alarcon B, Mestre D, Martinez-Martin N. The immunological synapse: a cause or consequence of T-cell receptor triggering? Immunology (2011) 133:420-5. doi:10.1111/j.1365-2567.2011.03458.x
74. Smith-Garvin JE, Koretzky GA, Jordan MS. T cell activation. Annu Rev Immunol (2009) 27:591-619. doi:10.1146/annurev.immunol.021908.132706
75. Marrack P, Mitchell T, Hildeman D, Kedl R, Teague TK, Bender J, et al. Genomic-scale analysis of gene expression in resting and activated T cells. Curr Opin Immunol (2000) 12:206-9. doi:10.1016/S0952-7915(99)00075-8
76. Rangel C, Angus J, Ghahramani Z, Lioumi M, Sotheran E, Gaiba A, et al. Modeling T-cell activation using gene expression profiling and state-space models. Bioinformatics (2004) 20:1361-72. doi:10.1093/bioinformatics/bth093
77. Reichardt P, Dornbach B, Rong S, Beissert S, Gueler F, Loser K, et al. Naive B cells generate regulatory T cells in the presence of a mature immunologic synapse. Blood (2007) 110:1519-29. doi:10.1182/blood-2006-10-053793
78. Revy P, Sospedra M, Barbour B, Trautmann A. Functional antigen-independent synapses formed between T cells and dendritic cells. Nat Immunol (2001) 2:925-31. doi:10.1038/ni713
79. Delon J, Bercovici N, Raposo G, Liblau R, Trautmann A. Antigen-dependent and -independent Ca2+ responses triggered in T cells by dendritic cells compared with B cells. J Exp Med (1998) 188:1473-84. doi:10.1084/jem.188.8.1473
80. Al-Alwan MM, Liwski RS, Haeryfar SM, Baldridge WH, Hoskin DW, Rowden G, et al. Cutting edge: dendritic cell actin cytoskeletal polarization during immunological synapse formation is highly antigen-dependent. J Immunol (2003) 171:4479-83. doi:10.4049/jimmunol.171.9.4479
81. Ramsay AG, Clear AJ, Kelly G, Fatah R, Matthews J, Macdougall F, et al. Follicular lymphoma cells induce T-cell immunologic synapse dysfunction that can be repaired with lenalidomide: implications for the tumor microenvironment and immunotherapy. Blood (2009) 114:4713-20. doi:10.1182/blood-2009-04-217687
82. Ramsay AG, Johnson AJ, Lee AM, Gorgun G, Le Dieu R, Blum W, et al. Chronic lymphocytic leukemia T cells show impaired immunological synapse formation that can be reversed with an immunomodulating drug. J Clin Invest (2008) 118:2427-37. doi:10.1172/jci35017
83. Gorgun G, Holderried TA, Zahrieh D, Neuberg D, Gribben JG. Chronic lymphocytic leukemia cells induce changes in gene expression of CD4 and CD8 T cells. J Clin Invest (2005) 115:1797-805. doi:10.1172/jci24176
84. Gorgun G, Ramsay AG, Holderried TA, Zahrieh D, Le Dieu R, Liu F, et al. E(mu)-TCL1 mice represent a model for immunotherapeutic reversal of chronic lymphocytic leukemia-induced T-cell dysfunction. Proc Natl Acad Sci U S A (2009) 106:6250-5. doi:10.1073/pnas.0901166106
85. Blanchard N, Di Bartolo V, Hivroz C. In the immune synapse, ZAP-70 controls T cell polarization and recruitment of signaling proteins but not formation of the synaptic pattern. Immunity (2002) 17:389-99. doi:10.1016/S1074-7613(02)00421-1
86. Morgan MM, Labno CM, Van Seventer GA, Denny MF, Straus DB, Burkhardt JK. Superantigen-induced T cell:B cell conjugation is mediated by LFA-1 and requires signaling through Lck, but not ZAP-70. J Immunol (2001) 167:5708-18. doi:10.4049/jimmunol.167.10.5708
87. Le Dieu R, Taussig DC, Ramsay AG, Mitter R, Miraki-Moud F, Fatah R, et al. Peripheral blood T cells in acute myeloid leukemia (AML) patients at diagnosis have abnormal phenotype and genotype and form defective immune synapses with AML blasts. Blood (2009) 114:3909-16. doi:10.1182/blood-2009-02-206946
88. Kiaii S, Clear AJ, Ramsay AG, Davies D, Sangaralingam A, Lee A, et al. Follicular lymphoma cells induce changes in T-cell gene expression and function: potential impact on survival and risk of transformation. J Clin Oncol (2013) 31:2654-61. doi:10.1200/jco.2012.44.2137
89. Wiernik PH, Lossos IS, Tuscano JM, Justice G, Vose JM, Cole CE, et al. Lenalidomide monotherapy in relapsed or refractory aggressive non-Hodgkin's lymphoma. J Clin Oncol (2008) 26:4952-7. doi:10.1200/jco.2007.15.3429
90. Witzig TE, Wiernik PH, Moore T, Reeder C, Cole C, Justice G, et al. Lenalidomide oral monotherapy produces durable responses in relapsed or refractory indolent non-Hodgkin's Lymphoma. J Clin Oncol (2009) 27:5404-9. doi:10.1200/jco.2008.21.1169
91. Zinzani PL, Vose JM, Czuczman MS, Reeder CB, Haioun C, Polikoff J, et al. Long-term follow-up of lenalidomide in relapsed/refractory mantle cell lymphoma: subset analysis of the NHL-003 study. Ann Oncol (2013) 24:2892-7. doi:10.1093/annonc/mdt366
92. Wang M, Fowler N, Wagner-Bartak N, Feng L, Romaguera J, Neelapu SS, et al. Oral lenalidomide with rituximab in relapsed or refractory diffuse large cell, follicular and transformed lymphoma: a phase II clinical trial. Leukemia (2013) 27:1902-9. doi:10.1038/leu.2013.95
93. Ahmadi T, Chong EA, Gordon A, Aqui NA, Nasta SD, Svoboda J, et al. Combined lenalidomide, low-dose dexamethasone, and rituximab achieves durable responses in rituximab-resistant indolent and mantle cell lymphomas. Cancer (2014) 120:222-8. doi:10.1002/cncr.28405
94. Wang M, Fayad L, Wagner-Bartak N, Zhang L, Hagemeister F, Neelapu SS, et al. Lenalidomide in combination with rituximab for patients with relapsed or refractory mantle-cell lymphoma: a phase 1/2 clinical trial. Lancet Oncol (2012) 13:716-23. doi:10.1016/s1470-2045(12)70200-0
95. Blake SJ, Ching ALH, Kenna TJ, Galea R, Large J, Yagita H, et al. Blockade of PD-1/PD-L1 promotes adoptive T-cell immunotherapy in a tolerogenic environment. PLoS One (2015) 10:e0119483. doi:10.1371/journal.pone.0119483
96. Goldberg MV, Maris CH, Hipkiss EL, Flies AS, Zhen L, Tuder RM, et al. Role of PD-1 and its ligand, B7-H1, in early fate decisions of CD8 T cells. Blood (2007) 110:186-92. doi:10.1182/blood-2006-12-062422
97. Brunner MC, Chambers CA, Chan FK, Hanke J, Winoto A, Allison JP. CTLA-4-mediated inhibition of early events of T cell proliferation. J Immunol (1999) 162:5813-20.
98. Barber DL, Wherry EJ, Masupost D, Zhu B, Allison JP, Sharpe AH, et al. Restoring function in exhausted CD8+ T cells during chronic viral infection. Nature (2006) 439:682-7. doi:10.1038/nature04444
99. Egen JG, Allison JP. Cytotoxic T lymphocyte antigen-4 accumulation in the immunological synapse is regulated by TCR signal strength. Immunity (2002) 16:23-35. doi:10.1016/S1074-7613(01)00259-X
100. Yokosuka T, Kobayashi W, Takamatsu M, Sakata-Sogawa K, Zeng H, Hashimoto-Tane A, et al. Spatiotemporal basis of CTLA-4 costimulatory molecule-mediated negative regulation of T cell activation. Immunity (2010) 33:326-39. doi:10.1016/j.immuni.2010.09.006
101. Collins AV, Brodie DW, Gilbert RJ, Iaboni A, Manso-Sancho R, Walse B, et al. The interaction properties of costimulatory molecules revisited. Immunity (2002) 17:201-10. doi:10.1016/S1074-7613(02)00362-X
102. Huse M. The T-cell-receptor signaling network. J Cell Sci (2009) 122:1269-73. doi:10.1242/jcs.042762
103. Xerri L, Devilard E, Hassoun J, Olive D, Birg F. In vivo expression of the CTLA4 inhibitory receptor in malignant and reactive cells from human lymphomas. J Pathol (1997) 183:182-7. doi:10.1002/(sici)1096-9896(199710)183:2<182:aid-path918>3.0.co;2-i
104. Ansell SM, Hurvitz SA, Koenig PA, LaPlant BR, Kabat BF, Fernando D, et al. Phase I study of ipilimumab, an anti-CTLA-4 monoclonal antibody, in patients with relapsed and refractory B-cell non-Hodgkin lymphoma. Clin Cancer Res (2009) 15:6446-53. doi:10.1158/1078-0432.ccr-09-1339
105. Bashey A, Medina B, Corringham S, Pasek M, Carrier E, Vrooman L, et al. CTLA4 blockade with ipilimumab to treat relapse of malignancy after allogeneic hematopoietic cell transplantation. Blood (2009) 113:1581-8. doi:10.1182/blood-2008-07-168468
106. Khorshied MM, Gouda HM, Khorshid OM. Association of cytotoxic T-lymphocyte antigen 4 genetic polymorphism, hepatitis C viral infection and B-cell non-Hodgkin lymphoma: an Egyptian study. Leuk Lymphoma (2014) 55:1061-6. doi:10.3109/10428194.2013.820294
107. Freeman GJ, Wherry EJ, Ahmed R, Sharpe AH. Reinvigorating exhausted HIV-specific T cells via PD-1-PD-1 ligand blockade. J Exp Med (2006) 203:2223-7. doi:10.1084/jem.20061800
108. West EE, Jin HT, Rasheed AU, Penaloza-Macmaster P, Ha SJ, Tan WG, et al. PD-L1 blockade synergizes with IL-2 therapy in reinvigorating exhausted T cells. J Clin Invest (2013) 123:2604-15. doi:10.1172/jci67008
109. Velu V, Titanji K, Zhu B, Husain S, Pladevega A, Lai L, et al. Enhancing SIV-specific immunity in vivo by PD-1 blockade. Nature (2009) 458:206-10. doi:10.1038/nature07662
110. Dong H, Strome SE, Salomao DR, Tamura H, Hirano F, Flies DB, et al. Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med (2002) 8:793-800. doi:10.1038/nm730
111. Thompson RH, Kuntz SM, Leibovich BC, Dong H, Lohse CM, Webster WS, et al. Tumor B7-H1 is associated with poor prognosis in renal cell carcinoma patients with long-term follow-up. Cancer Res (2006) 66:3381-5. doi:10.1158/0008-5472.can-05-4303
112. Ohigashi Y, Sho M, Yamada Y, Tsurui Y, Hamada K, Ikeda N, et al. Clinical significance of programmed death-1 ligand-1 and programmed death-1 ligand-2 expression in human esophageal cancer. Clin Cancer Res (2005) 11:2947-53. doi:10.1158/1078-0432.ccr-04-1469
113. Hino R, Kabashima K, Kato Y, Yagi H, Nakamura M, Honjo T, et al. Tumor cell expression of programmed cell death-1 ligand 1 is a prognostic factor for malignant melanoma. Cancer (2010) 116:1757-66. doi:10.1002/cncr.24899
114. Green MR, Monti S, Rodig SJ, Juszczynski P, Currie T, O'Donnell E, et al. Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma. Blood (2010) 116:3268-77. doi:10.1182/blood-2010-05-282780
115. Rossille D, Gressier M, Damotte D, Maucort-Boulch D, Pangault C, Semana G, et al. High level of soluble programmed cell death ligand 1 in blood impacts overall survival in aggressive diffuse large B-Cell lymphoma: results from a French multicenter clinical trial. Leukemia (2014) 28:2367-75. doi:10.1038/leu.2014.137
116. Wang L, Qian J, Lu Y, Li H, Bao H, He D, et al. Immune evasion of mantle cell lymphoma: expression of B7-H1 leads to inhibited T-cell response to and killing of tumor cells. Haematologica (2013) 98:1458-66. doi:10.3324/haematol.2012.071340
117. Zhang L, Gajewski TF, Kline J. PD-1/PD-L1 interactions inhibit antitumor immune responses in a murine acute myeloid leukemia model. Blood (2009) 114:1545-52. doi:10.1182/blood-2009-03-206672
118. Sheppard KA, Fitz LJ, Lee JM, Benander C, George JA, Wooters J, et al. PD-1 inhibits T-cell receptor induced phosphorylation of the ZAP70/CD3zeta signalosome and downstream signaling to PKCtheta. FEBS Lett (2004) 574:37-41. doi:10.1016/j.febslet.2004.07.083
119. Yokosuka T, Takamatsu M, Kobayashi-Imanishi W, Hashimoto-Tane A, Azuma M, Saito T. Programmed cell death 1 forms negative costimulatory microclusters that directly inhibit T cell receptor signaling by recruiting phosphatase SHP2. J Exp Med (2012) 209:1201-17. doi:10.1084/jem.20112741
120. Pentcheva-Hoang T, Chen L, Pardoll DM, Allison JP. Programmed death-1 concentration at the immunological synapse is determined by ligand affinity and availability. Proc Natl Acad Sci U S A (2007) 104:17765-70. doi:10.1073/pnas.0708767104
121. Fife BT, Pauken KE, Eagar TN, Obu T, Wu J, Tang Q, et al. Interactions between PD-1 and PD-L1 promote tolerance by blocking the TCR-induced stop signal. Nat Immunol (2009) 10:1185-92. doi:10.1038/ni.1790
122. Ramsay AG, Clear AJ, Fatah R, Gribben JG. Multiple inhibitory ligands induce impaired T-cell immunologic synapse function in chronic lymphocytic leukemia that can be blocked with lenalidomide: establishing a reversible immune evasion mechanism in human cancer. Blood (2012) 120:1412-21. doi:10.1182/blood-2012-02-411678
123. Topalian SL, Sznol M, McDermott DF, Kluger HM, Carvajal RD, Sharfman WH, et al. Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. J Clin Oncol (2014) 32:1020-30. doi:10.1200/jco.2013.53.0105
124. Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med (2012) 366:2443-54. doi:10.1056/NEJMoa1200690
125. Berger R, Rotem-Yehudar R, Slama G, Landes S, Kneller A, Leiba M, et al. Phase I safety and pharmacokinetic study of CT-011, a humanized antibody interacting with PD-1, in patients with advanced hematologic malignancies. Clin Cancer Res (2008) 14:3044-51. doi:10.1158/1078-0432.ccr-07-4079
126. Armand P, Nagler A, Weller EA, Devine SM, Avigan DE, Chen YB, et al. Disabling immune tolerance by programmed death-1 blockade with pidilizumab after autologous hematopoietic stem-cell transplantation for diffuse large B-cell lymphoma: results of an international phase II trial. J Clin Oncol (2013) 31:4199-206. doi:10.1200/jco.2012.48.3685
127. Westin JR, Chu F, Zhang M, Fayad LE, Kwak LW, Fowler N, et al. Safety and activity of PD1 blockade by pidilizumab in combination with rituximab in patients with relapsed follicular lymphoma: a single group, open-label, phase 2 trial. Lancet Oncol (2014) 15:69-77. doi:10.1016/s1470-2045(13)70551-5
128. Bachy E, Coiffier B. Anti-PD1 antibody: a new approach to treatment of lymphomas. Lancet Oncol (2014) 15:7-8. doi:10.1016/s1470-2045(13)70587-4
129. Ramsay AG, Evans R, Kiaii S, Svensson L, Hogg N, Gribben JG. Chronic lymphocytic leukemia cells induce defective LFA-1-directed T-cell motility by altering Rho GTPase signaling that is reversible with lenalidomide. Blood (2013) 121:2704-14. doi:10.1182/blood-2012-08-448332
130. Scholer A, Hugues S, Boissonnas A, Fetler L, Amigorena S. Intercellular adhesion molecule-1-dependent stable interactions between T cells and dendritic cells determine CD8+ T cell memory. Immunity (2008) 28:258-70. doi:10.1016/j.immuni.2007.12.016
131. Hilchey SP, Hyrien O, Mosmann TR, Livingstone AM, Friedberg JW, Young F, et al. Rituximab immunotherapy results in the induction of a lymphoma idiotype-specific T-cell response in patients with follicular lymphoma: support for a "vaccinal effect" of rituximab. Blood (2009) 113:3809-12. doi:10.1182/blood-2008-10-185280
132. Teague RM, Greenberg PD, Fowler C, Huang MZ, Tan X, Morimoto J, et al. Peripheral CD8+ T cell tolerance to self-proteins is regulated proximally at the T cell receptor. Immunity (2008) 28:662-74. doi:10.1016/j.immuni.2008.03.012
133. Choi S, Schwartz RH. Impairment of immunological synapse formation in adaptively tolerant T cells. J Immunol (2011) 187:805-16. doi:10.4049/jimmunol.1003314
134. Carlin LM, Yanagi K, Verhoef A, Nolte-'t Hoen EN, Yates J, Gardner L, et al. Secretion of IFN-gamma and not IL-2 by anergic human T cells correlates with assembly of an immature immune synapse. Blood (2005) 106:3874-9. doi:10.1182/blood-2005-03-0996
135. Ise W, Nakamura K, Shimizu N, Goto H, Fujimoto K, Kaminogawa S, et al. Orally tolerized T cells can form conjugates with APCs but are defective in immunological synapse formation. J Immunol (2005) 175:829-38. doi:10.4049/jimmunol.175.2.829
136. Zambricki E, Zal T, Yachi P, Shigeoka A, Sprent J, Gascoigne N, et al. In vivo anergized T cells form altered immunological synapses in vitro. Am J Transplant (2006) 6:2572-9. doi:10.1111/j.1600-6143.2006.01517.x
137. Doherty M, Osborne DG, Browning DL, Parker DC, Wetzel SA. Anergic CD4+ T cells form mature immunological synapses with enhanced accumulation of c-Cbl and Cbl-b. J Immunol (2010) 184:3598-608. doi:10.4049/jimmunol.0902285
138. Dumont C, Blanchard N, Di Bartolo V, Lezot N, Dufour E, Jauliac S, et al. TCR/CD3 down-modulation and zeta degradation are regulated by ZAP-70. J Immunol (2002) 169:1705-12. doi:10.4049/jimmunol.169.4.1705
139. Jenkins MR, Tsun A, Stinchcombe JC, Griffiths GM. The strength of T cell receptor signal controls the polarization of cytotoxic machinery to the immunological synapse. Immunity (2009) 31:621-31. doi:10.1016/j.immuni.2009.08.024
140. Gombos I, Detre C, Vamosi G, Matko J. Rafting MHC-II domains in the APC (presynaptic) plasma membrane and the thresholds for T-cell activation and immunological synapse formation. Immunol Lett (2004) 92:117-24. doi:10.1016/j.imlet.2003.11.022
141. Anderson HA, Hiltbold EM, Roche PA. Concentration of MHC class II molecules in lipid rafts facilitates antigen presentation. Nat Immunol (2000) 1:156-62. doi:10.1038/77842
142. Hiltbold EM, Poloso NJ, Roche PA. MHC class II-peptide complexes and APC lipid rafts accumulate at the immunological synapse. J Immunol (2003) 170:1329-38. doi:10.4049/jimmunol.170.3.1329